Unitaid audited financial report for the year ended 31 December 2022
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Overview of mpox antivirals and diagnostics landscape
Next generation pulse oximeters technology and market landscape
Malaria diagnostics market and technology landscape
Landscape of innovative tools and delivery strategies for eliminating vertical transmission of HIV, syphilis, hepatitis B, and chagas in endemic areas
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Biomarkers for acute febrile illness at the point-of-care in low-resource settings. Meeting report
Accelerating access to innovative point-of-care HIV diagnostics: Lessons learned from UNICEF
Innovative delivery systems for paediatric medicines technology landscape
Disease Narrative for hepatitis C
Disease narrative for tuberculosis
Disease Narrative for malaria
Disease Narrative for HIV
Hepatitis C diagnostics technology landscape – May 2019
Unitaid and the Government of Spain
About Unitaid (Saving lives faster)
Unitaid and the UK Government
Unitaid audited financial report for the year ended 31 December 2023
Partnership report: Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Unitaid audited financial report for the year ended 31 December 2022
Annual report 2016 – 2017
Unitaid audited financial report for the year ended 31 December 2017
Methodology for developing strategic narratives
Landscape for HIV rapid diagnostic tests for HIV self-testing – 3rd edition – July 2016
Landscape for HIV rapid diagnostic tests for HIV self-testing – 3rd edition – July 2016
Key Performance Indicators 2016
Global malaria diagnostic and artemisinin treatment commodities demand forecast: 2017 – 2020: Report (May 2017)
